碩士生萬秀珍論文J Biomed Mater Res. A 發表
J Biomed Mater Res. 2020;108A:292–300.
TOPIC: Poly(ε-caprolactone)/keratin/heparin/VEGF biocomposite mats for vascular tissue engineering
Abstract
Vascular endothelial growth factor (VEGF) is an effective growth and angiogenic cytokine, which stimulates proliferation and survival of endothelial cells, and promotes angiogenesis and vascular permeability. Binding VEGF with heparin could protect it from rapid degradation, subsequently allowing it to be controlled release. Primarily, poly(ε-caprolactone) (PCL) and keratin were coelectrospun, followed by conjugating with heparin and subsequently binding VEGF. The loaded heparin and VEGF on these mats were quantified, respectively. The surface characteristics of mats were investigated by scanning electron microscopy (SEM) and X-ray photoelectron spectroscopy (XPS). The VEGF delivery results indicated these mats could sustainably release VEGF for 2 weeks. Cell viability assays suggested these mats were valid to accelerate human umbilical vein endothelial cells (HUVECs) proliferation, while inhibit human umbilical arterial smooth muscle cells (HUASMCs) growth under the combined actions of VEGF and heparin. The results tested by blood clotting times (APTT, PT, and TT), hemolysis,and platelet adhesion indicated the mats were blood compatible. To sum up, these biocomposite mats are ideal scaffolds for vascular tissue engineering.